BOCA RATON, Fla., March 8, 2012 /PRNewswire/ -- Biotest Pharmaceuticals Corporation (BPC), a wholly-owned subsidiary of Biotest AG (Dreieich, Germany), announced the appointment of Jordan Siegel as the Company’s Chief Executive Officer, effective May 1, 2012. Dr. Georg Floss, BPC’s interim CEO, will be returning to Germany on April 30th after successfully completing his assignment to assume the role of Global Head of Operations for Biotest AG.
“I would like to thank Dr. Floss for his leadership in successfully completing the technical expansion and restarting of the IgG production facility in Boca Raton as well as for his significant contributions to the organization during the past year,” stated Prof. Dr. Gregor Schulz, Chief Executive Officer of Biotest AG. “We are fortunate to have someone of Jordan’s caliber to continue BPC’s future growth.”
Mr. Siegel has been BPC’s Senior Vice President, Finance and Chief Financial Officer since the Company’s inception in 2007. Mr. Siegel has more than 20 years of international financial and operational experience including several key leadership positions with IVAX Corporation. Mr. Siegel holds a Bachelor’s degree in Finance from the University of Florida, a Bachelor’s degree in Accounting from Florida Atlantic University, an MBA in Finance from Florida Atlantic University and is a Certified Public Accountant.
About Biotest Pharmaceuticals Corporation
Biotest Pharmaceuticals Corporation, a wholly owned subsidiary of Biotest AG, researches, develops and manufactures biotherapeutic products with a specialization in immunology and hematology. BPC is a leader in the collection of source plasma and is currently involved in the development of plasma protein products in the field of Primary Immune Deficiency (PID) and various hyperimmune (IG) products. The Company owns and manages twelve plasmapherisis centers across the United States and a state-of-the-art manufacturing facility in Boca Raton, Florida. The Company employs more than 600 people in the U.S.
About Biotest AG
Biotest AG is a provider of pharmaceutical and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of application of clinical immunology, hematology and intensive medicine. In its Plasma Protein segment, Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. Biotest has more than 1,600 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.
SOURCE Biotest Pharmaceuticals Corporation
